Nucleus Network is a global early-phase clinical trial network supporting pharma and biotechs in Phase I and Ib development. We deliver FIH, SAD/MAD and PoC studies through integrated clinics in the UK (Hammersmith Medical Research) , USA and Australia, with strong PK and translational expertise.
Cooperation possibilities
Early-phase clinical development partnerships for pharma and biotechs, including FIH, SAD/MAD and PoC studies, adaptive designs, integrated PK/PD and translational support, with rapid startup and execution in proprietary clinics in the UK, USA and Australia.
- https://www.nucleusnetwork.com/contact/
- +44 20 8961 4130
- Send an email
- Olivier Simon
Some insights
Nucleus Network accelerates the development of new medicines by delivering high-quality early-phase clinical trials. We help innovative therapies reach patients faster, safely and ethically, through rigorous science, efficient execution and patient-focused care.
We are proud to enable innovative medicines to move safely and rapidly from laboratory to clinic. Our teams combine scientific excellence, operational speed and patient care to support biotech and pharma in making meaningful therapeutic progress.
We are inspired by organisations and leaders who combine scientific excellence, ethical clinical research and patient-centricity, including innovators advancing translational medicine, adaptive trial designs and responsible use of data to accelerate drug development.
Our team’s core strengths are early-phase clinical execution, PK and translational expertise, and fast, high-quality delivery across global sites. We plan to further strengthen regulatory strategy, biometrics and sponsor-facing scientific leadership.
They would say we help turn scientific ideas into new medicines by running early clinical studies, working with doctors and volunteers to test treatments safely so patients can benefit sooner.
By engaging early on upcoming assets, sharing development roadmaps, and fostering open collaboration, the Swiss biotech ecosystem can help align early-phase clinical strategies and accelerate efficient transition from preclinical to first-in-human studies.
Swiss biotech and pharma R&D leaders, clinical development and translational teams, procurement and outsourcing groups, and investors involved in early-stage asset development seeking high-quality Phase I- Ib clinical execution.
